The most impressive clinical effects observed with HSP90 inhibitor monotherapy have arisen in defined subsets of tumors that exhibit a high degree of oncogenic dependence on particular client proteins e.g., ALK-driven non-small cell lung cancer and HER2-amplified breast cancer [24]. Here, ERBB2 is linked to non-small cell lung carcinoma.